- Home
- NXC vs MDXH Comparison
NXC vs MDXH Comparison
Compare NXC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- MDXH
- Stock Information
- Founded
- NXC 1992
- MDXH 2003
- Country
- NXC United States
- MDXH Belgium
- Employees
- NXC N/A
- MDXH N/A
- Industry
- NXC Investment Managers
- MDXH
- Sector
- NXC Finance
- MDXH
- Exchange
- NXC Nasdaq
- MDXH Nasdaq
- Market Cap
- NXC 87.3M
- MDXH 93.1M
- IPO Year
- NXC N/A
- MDXH 2021
- Fundamental
- Price
- NXC $13.13
- MDXH $2.26
- Analyst Decision
- NXC
- MDXH Strong Buy
- Analyst Count
- NXC 0
- MDXH 2
- Target Price
- NXC N/A
- MDXH $7.00
- AVG Volume (30 Days)
- NXC 17.5K
- MDXH 137.5K
- Earning Date
- NXC 01-01-0001
- MDXH 11-06-2024
- Dividend Yield
- NXC 3.97%
- MDXH N/A
- EPS Growth
- NXC N/A
- MDXH N/A
- EPS
- NXC 0.19
- MDXH N/A
- Revenue
- NXC N/A
- MDXH $84,708,000.00
- Revenue This Year
- NXC N/A
- MDXH $27.57
- Revenue Next Year
- NXC N/A
- MDXH $20.09
- P/E Ratio
- NXC $70.47
- MDXH N/A
- Revenue Growth
- NXC N/A
- MDXH 33.01
- 52 Week Low
- NXC $11.86
- MDXH $1.55
- 52 Week High
- NXC $13.70
- MDXH $4.64
- Technical
- Relative Strength Index (RSI)
- NXC 39.78
- MDXH 57.11
- Support Level
- NXC $13.15
- MDXH $2.12
- Resistance Level
- NXC $13.29
- MDXH $2.52
- Average True Range (ATR)
- NXC 0.16
- MDXH 0.16
- MACD
- NXC -0.01
- MDXH 0.01
- Stochastic Oscillator
- NXC 23.44
- MDXH 61.19
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing primarily in municipal obligations.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.